Centene Corporation (CNC)

FairStock Score: 57/100 — STEADY

Key Financials

Strengths

• Dominant scale with $49.7B quarterly revenue across diversified Medicaid, Medicare, and Commercial segments
• Strong free cash flow generation of $5.1B demonstrates underlying cash production despite accounting losses
• Low beta of 0.46 provides defensive characteristics in market downturns
• Book value discount (P/B 0.85) reflects market skepticism, offering potential upside if turnaround succeeds

Concerns

• Latest quarter net loss of $1.1B with negative 2.21% margin indicates severe operational distress, not temporary weakness
• Catastrophic negative 28.68% ROE and 1.01% ROCE prove the business is destroying shareholder capital at an alarming rate
• Altman Z-Score of 1.04 places company in financial distress zone with elevated bankruptcy risk implications
• Negative earnings eliminate traditional valuation anchors; unclear when/if profitability returns

AI Analysis

Centene presents a challenging case that troubles me deeply. Here's a company with $49.7B in quarterly revenue—substantial scale—yet it's burning shareholder value spectacularly. The latest quarter showed a $1.1B net loss on a negative 2.21% margin. This isn't a temporary blip; it's a structural problem. The Piotroski F-Score of 5/9 signals deteriorating financial quality, while the Altman Z-Score of 1.04 sits dangerously in distress territory. Most alarming: negative 28.68% ROE and a pathetic 1.01% ROCE. These metrics tell me Centene destroys capital, not builds it. The company's debt-to-equity of 0.91 compounds this problem—they're leveraged while unprofitable. Yes, they generate $5.1B in free cash flow, but that's merely cash from operations before the avalanche of capital needs. The P/B of 0.85 might suggest value, but Graham taught us never to catch a falling knife. With a FairStock Score of 45/100, this is uninvestable at current conditions. The managed care business offers competitive advantages when executed well, but Centene appears to be losing that execution battle. I need to see sustained profitability, positive ROE, and evidence of pricing power before reconsidering.

Bull Case

If management successfully executes cost controls and regulatory headwinds ease, Centene's massive scale and market share could translate to normalized 3-4% margins, driving the $5.1B FCF to shareholders. The company's low beta and defensive positioning in healthcare could attract value investors once profitability stabilizes.

Bear Case

Persistent losses could erode the balance sheet faster than FCF can replenish it, especially with 0.91 D/E ratio. If competitive pressures worsen or medical cost inflation accelerates beyond pricing power, Centene risks covenant violations and potential equity restructuring.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer